ABA Editorial · Dec 3, 2025 · 14 min read
African populations are dramatically under-represented in global genomic databases, with more than 80 percent of participants in genome-wide association studies historically of European descent. This gap has implications for precision medicine, drug development, and disease research. The collapse of 54gene illustrated the difficulty of building genomics at commercial scale. This report maps the landscape.
African populations are dramatically under-represented in global genomic databases, with historical estimates suggesting that more than 80 percent of participants in genome-wide association studies have been of European descent. This gap has significant implications. Precision medicine approaches that rely on genetic information to guide treatment decisions may produce less accurate recommendations for African patients because the underlying data was not collected from populations similar to theirs. Drug development that relies on genetic insights for target identification may miss mechanisms that are particularly relevant to African disease profiles. And research into diseases that disproportionately affect African populations (sickle cell disease, certain infectious diseases, specific cancer subtypes) may have progressed more slowly than warranted by the underlying burden because the research infrastructure has been concentrated elsewhere. African genomics aims to address these gaps by building local research and commercial capacity for genomic science. The ambitions have been significant. The commercial execution has been difficult. This report maps the landscape, the high-profile 54gene collapse, and the path forward.
The specific problem is that human genetic variation is not evenly distributed across populations. Different groups have different frequencies of specific genetic variants, and some variants are common in some populations while rare in others. Pharmacogenomics (the study of how genetic variation affects drug response) produces results that depend on which populations were studied. A drug dosing recommendation based on genetic testing that was developed using primarily European study populations may be inaccurate when applied to African patients whose genetic profiles differ in relevant ways. Similarly, genetic risk predictions for diseases including cancer, cardiovascular disease, and diabetes may have different accuracy across populations depending on the training data used.
The implications extend beyond clinical applications to drug development itself. When pharmaceutical companies identify drug targets through genetic research, the targets they identify are influenced by which populations their research examined. Diseases and disease subtypes that are more common in African populations may receive less research attention because the researchers and databases driving target identification have historically been less focused on African health priorities.
54gene was founded in Nigeria with ambitions to build an African genomics company that would address the representation gap while creating commercial value. The company raised significant venture capital, attracted international attention for its mission, and built operational infrastructure including sample collection, laboratory capacity, and partnerships with pharmaceutical companies interested in African genomic data. At its peak, 54gene was one of the most visible African healthtech companies and was frequently cited as evidence that African operators could build commercially successful companies addressing globally significant health research gaps.
The company collapsed through a difficult period that included internal governance challenges, operational restructuring, staff departures, and ultimately the shutdown of its primary business lines. The reasons for the collapse have been discussed extensively in industry coverage, and multiple factors contributed including commercial sustainability challenges, internal organizational issues, and the broader funding environment contraction that affected African healthtech during 2023.
The 54gene experience offers several lessons. First, genomics is a capital-intensive category that requires sustained long-term investment before commercial returns can materialize. Second, building African commercial demand for genomic services is more difficult than research-oriented narratives sometimes acknowledge, because the domestic market for precision medicine applications is small. Third, reliance on international pharmaceutical partnerships creates dependency on decisions made outside Africa that can shift in ways the operator cannot control. These lessons do not mean that African genomics cannot succeed, but they do mean that future operators will need to approach the category with more realistic expectations about timelines, capital requirements, and commercial paths to viability.
A distinct alternative to commercial African genomics is the research-driven model, where African genomic capacity is built through academic institutions, government programs, and international research partnerships rather than through venture-backed commercial operators. This model has produced substantive outputs including the H3Africa consortium, which has supported genomic research across multiple African countries and institutions, and several country-specific initiatives in South Africa, Kenya, Nigeria, and elsewhere.
The research-driven model has different economics than the commercial model. It depends on grant funding, international collaborations, and academic career incentives rather than on commercial returns. It produces scientific publications, trained scientists, and sample collections that support broader research, but it does not directly generate revenue that could sustain long-term commercial operations. Whether this model can eventually spin out commercial applications, or whether commercial and research genomics are fundamentally different categories that require different institutional structures, is an open question.
Sickle cell disease is a particularly relevant category for African genomics because the disease is strongly concentrated in African populations, affecting tens of millions of people across the continent. Research into sickle cell genetics, therapeutic approaches (including gene therapies that have shown promising results in recent years), and preventive strategies has been driven in part by African research institutions and international collaborations focused specifically on the disease. The potential commercialization of gene therapies for sickle cell disease creates a specific commercial pathway where African genomics could matter directly for African patients, though the cost structures of current gene therapy approaches make affordability a major concern.
African genomic research raises questions about data sovereignty that have become politically important in several countries. Genomic data derived from African populations has commercial and scientific value, and there are concerns that this value will be captured by international companies or researchers rather than flowing back to the populations and countries that contributed the samples. Policy responses have included data-sharing agreements that preserve rights for contributing institutions, limits on export of raw genomic data, and requirements for benefit-sharing that would return commercial value to African stakeholders.
These policies are necessary and legitimate but also create friction that can slow collaborative research and commercial deployment. Balancing the protection of African genomic sovereignty with the benefits of international collaboration is an ongoing policy negotiation in multiple African countries.
Three indicators will shape African genomics. First, whether any new commercial operators emerge in the space following the 54gene experience, or whether commercial genomics capacity continues to be constrained by the difficulty of the business model. Second, whether research-driven capacity continues to expand through academic institutions and international collaborations, maintaining African participation in global genomic science even without commercial scale. Third, whether gene therapies for sickle cell disease and other conditions become accessible in African markets at affordable price points, which would create the first large-scale precision medicine demand the continent has seen. African genomics has significant potential but has faced significant execution challenges, and the next phase of development depends on learning from the lessons of the first phase.